You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
山東新華製藥股份(00719.HK)與真實生物簽訂戰略合作協議 公司並非真實生物唯一合作方

格隆匯4月27日丨山東新華製藥股份(00719.HK)公吿,公司於2022年4月26日已與河南真實生物科技有限公司(“真實生物”)簽訂戰略合作協議,據此真實生物同意新華製藥為其擁有的相關產品在中國及經雙方同意的其他國家的產品生產商和經銷商。

作為一家擁有cGMP(Current Good Manufacturing Practices for Pharmaceutical Products)藥品生產能力的中國製藥公司,該協議是雙方未來合作的框架,公司將根據雙方協議為真實生物生產藥品和醫藥產品,並依照註冊文件中規定的相關要求為真實生物生產相關產品,滿足真實生物在中國及潛在的國際市場的註冊和銷售需求。

雙方應進一步協商並簽訂進一步協議(包括委託製造協議和技術質量協議),以執行和實施合作,這些協議將本着公平合理的原則以合規方式訂立。該協議的有效期為十年,除非雙方同意或根據該協議的規定終止。

董事會認為,訂立該協議對公司有利,本協議的簽署有利於公司現代醫藥國際合作中心產能發揮及產生收入的前景。 然而,目前無法確定簽訂該協議對公司財務業績和經營業績的影響,因為它 (i) 有待協商、簽署和簽訂進一步協議(包括委託製造協議和技術質量協議)用於執行和實施協議所設想的基礎項目(特別是,該協議僅作為未來可能與真實生物進行戰略合作的初步框架,迄今為止尚未就任何特定藥品和醫藥產品的合作達成任何協議。

此外,該協議具有非排他性,本公司並非真實生物的唯一合作方); (ii) 實質上取決於該協議所設想的基礎項目的實際實施和推廣(如有);及 (iii) 可能受國家政策變化、當前行業和市場環境以及其他風險和不確定性等多種因素的影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account